Skip to main content

Table 9 Proportions of resistance to second-line injectable drugs and streptomycin stratified by age groups

From: Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study

 

15–34

35–59

≥60

Total

p-value

Non-multidrug-resistance TB

692 (100.0%)

1512 (100.0%)

2034 (100.0%)

4238 (100.0%)

 

 Resistance to any SLIDa

2 (0.3%)

2 (0.1%)

12 (0.6%)

16 (0.4%)

0.082

 Km resistance

0 (0.0%)

1 (0.1%)

6 (0.3%)

7 (0.2%)

0.127

 Am resistance

0 (0.0%)

1 (0.1%)

5 (0.2%)

6 (0.1%)

0.207

 Cm resistance

2 (0.3%)

2 (0.1%)

10 (0.5%)

14 (0.3%)

0.179

 Sm resistance

16 (2.3%)

37 (2.4%)

56 (2.8%)

109 (2.6%)

0.761

Multidrug-resistance TB

42 (100.0%)

81 (100.0%)

56 (100.0%)

179 (100.0%)

 

 Resistance to any SLIDa

5 (11.9%)

14 (17.3%)

7 (12.5%)

26 (14.5%)

0.633

 Km resistance

4 (9.5%)

13 (16.0%)

7 (12.5%)

24 (13.4%)

0.585

 Am resistance

4 (9.5%)

10 (12.3%)

7 (12.5%)

21 (11.7%)

0.878

 Cm resistance

3 (7.1%)

10 (12.3%)

7 (12.5%)

20 (11.2%)

0.638

 Sm resistance

15 (35.7%)

24 (29.6%)

20 (35.7%)

59 (33.0%)

0.690

  1. Abbreviations: TB tuberculosis, SLID second-line injectable drug, Km kanamycin, Am amikacin, Cm capreomycin, Sm streptomycin
  2. aAny second-line injectable drugs refer to kanamycin, amikacin, or capreomycin